Financial Review: Response Genetics (OTCMKTS:RGDXQ) & Femasys (NASDAQ:FEMY)

Femasys (NASDAQ:FEMY) and Response Genetics (OTCMKTS:RGDXQ) are both medical companies, but which is the superior business? We will compare the two companies based on the strength of their analyst recommendations, profitability, valuation, institutional ownership, earnings, dividends and risk.

Analyst Recommendations

This is a summary of recent ratings and price targets for Femasys and Response Genetics, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Femasys	1	0	3	0	2.50
Response Genetics	0	0	0	0	0.00

Femasys currently has a consensus price target of $6.83, indicating a potential upside of 693.56%. Given Femasys’ stronger consensus rating and higher possible upside, research analysts clearly believe Femasys is more favorable than Response Genetics.

Insider & Institutional Ownership

65.3% of Femasys shares are owned by institutional investors. 11.5% of Femasys shares are owned by company insiders. Comparatively, 4.9% of Response Genetics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Profitability

This table compares Femasys and Response Genetics’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Femasys	-960.80%	-764.26%	-141.97%
Response Genetics	N/A	N/A	N/A

Valuation and Earnings

This table compares Femasys and Response Genetics”s top-line revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Femasys	$1.63 million	30.89	-$18.82 million	($0.72)	-1.20
Response Genetics	N/A	N/A	N/A	N/A	N/A

Response Genetics has lower revenue, but higher earnings than Femasys.

Summary

Femasys beats Response Genetics on 6 of the 9 factors compared between the two stocks.

About Femasys

Femasys Inc., a biomedical company, develops therapeutic and diagnostic solutions to address unmet women healthcare needs worldwide. The company provides FemVue saline-air device, a contrast-generating product in the United States, Canada, Japan, and Hong Kong; FemCath, a cornual balloon catheter, a single intrauterine directional delivery product that allows for selective evaluation of an individual fallopian tube; and FemCerv, a biopsy device for endocervical curettage, which can be used to sample cervical cells and tissue circumferentially with sample containment within the device to minimize contamination. It also develops permanent birth control solutions, such as FemBloc and FemChec; FemaSeed, an artificial insemination solution; and FemEMB, a product candidate for endometrial sampling in support of uterine cancer detection testing. The company offers its products to reproductive endocrinologists for infertility products, obstetrics-gynecological physicians, related healthcare professionals, and women's healthcare provider organizations. Femasys Inc. was incorporated in 2004 and is headquartered in Suwanee, Georgia.

About Response Genetics

Response Genetics, Inc., a life sciences company, researches, develops, markets, and sells pharmacogenomic tests for use in the treatment of cancer in the United States, Europe, and internationally. The company offers tests for measuring predictive factors for therapy response in tumor tissue samples. It provides testing services for non-small cell lung cancer, colorectal cancer, gastric and gastroesophageal cancer, melanoma and thyroid cancer, breast cancer, and glioma through its ResponseDX: Lung, ResponseDX: Colon, ResponseDX: Gastric, ResponseDX: Melanoma, ResponseDX: Thyroid, ResponseDX: Breast, ResponseDX: Glioma, and ResponseDX: Tissue of Origin test suites. The company also develops tests for other tumor types; and provides technical component and professional component testing services. It serves community based oncologists, pathologists, physician offices, hospitals, and pharmaceutical companies through its sales force. The company was formerly known as Bio Type, Inc. and changed its name to Response Genetics, Inc. in August 2000. Response Genetics, Inc. was founded in 1999 and is headquartered in Los Angeles, California.